Genmab A/S Grant Of Restricted Stock Units And Warrants To Employees In Genmab
October 07 2021 - 1:55PM
UK Regulatory
TIDMGEN
Company Announcement
COPENHAGEN, Denmark; October 7, 2021 --
https://www.globenewswire.com/Tracker?data=U_E_kJKdJxKw7rqx0bFTkZZVHWUq6sgOr4thgJwlla2qNBSZr7qbq-3dkbOnzpEOrDBxIgpgDFDBydHcbMMNmw==
Genmab A/S (Nasdaq: GMAB) announced today that at a board meeting
the board decided to grant 18,689 restricted stock units and 21,537
warrants to employees of the company and three of the company's
subsidiaries.
Each restricted stock unit is awarded cost-free and provides the
owner with a right to receive one share in Genmab A/S of nominally
DKK 1. The fair value of each restricted stock unit is equal to the
closing market price on the date of grant of one Genmab A/S share,
DKK 2,806.
The restricted stock units will vest on the first banking day of
the month following a period of three years from the date of grant.
Furthermore, the restricted stock units are subject to vesting
conditions set out in the restricted stock unit program adopted by
the board of directors in accordance with the Remuneration Policy
adopted by the shareholders at the annual general meeting.
Information concerning Genmab's restricted stock unit program can
be found on www.genmab.com under Investors > Governance >
Compensation > Restricted stock units.
The exercise price for each warrant is DKK 2,806. Each warrant
is awarded cost-free and entitles the owner to subscribe one share
of nominally DKK 1 subject to payment of the exercise price. By
application of the Black-Scholes formula, the fair value of each
warrant can be calculated as DKK 812.15.
The warrants vest three years after the grant date, and all
warrants expire at the seventh anniversary of the grant date. The
new warrants have been granted on the terms and conditions set out
in the warrant program adopted by the board of directors on
February 23, 2021. Information concerning Genmab's warrant schemes
can be found on www.genmab.com under Investors > Governance >
Compensation > Warrants.
About Genmab
Genmab is an international biotechnology company with a core
purpose to improve the lives of people with cancer. For more than
20 years, Genmab's vision to transform cancer treatment has driven
its passionate, innovative and collaborative teams to invent
next-generation antibody technology platforms and leverage
translational research and data sciences, fueling multiple
differentiated cancer treatments that make an impact on people's
lives. To develop and deliver novel therapies to patients, Genmab
has formed 20+ strategic partnerships with biotechnology and
pharmaceutical companies. Genmab's proprietary pipeline includes
bispecific T-cell engagers, next-generation immune checkpoint
modulators, effector function enhanced antibodies and antibody-drug
conjugates.
Genmab is headquartered in Copenhagen, Denmark with locations in
Utrecht, the Netherlands, Princeton, New Jersey, U.S. and Tokyo,
Japan. For more information, please visit Genmab.com
https://www.globenewswire.com/Tracker?data=U_E_kJKdJxKw7rqx0bFTkc8wRCiV0q8HkrnPWCassORDP6PIb3cwfEsD4b6NLmZYXqbmZOxHgWI7DcmEOSxFn-LOlKMXw_dxgtjgKsF4Ksa9_ZL6wrt1LJ6EUW102GeUSEE_Uv4nlwDLTtXcpxDPMA==
and follow us on Twitter.com/Genmab
https://www.globenewswire.com/Tracker?data=6uppbEvAYqa_PebQhixW1pcSOY6oJmovrD5xVT7l-NPZsCDLvHVc9QzWg5kYEE7aNx4IlDtQcLCWWbNSwhMeDwct3dyvxwIgM67jusjxEKg=
.
Contact:
Marisol Peron, Senior Vice President, Global Investor Relations
& Communications
T: +1 609 524 0065; E: mmp@genmab.com
https://www.globenewswire.com/Tracker?data=KOwN3wrpqgrGxKMZssAbYnlyaWqlrJDdIzEMPbM5G8lLNGuD1Slxognkgr3WvyNtftM0LcJzJPaaF3m7dvcH5w==
For Investor Relations:
Andrew Carlsen, Vice President, Head of Investor Relations
T: +45 3377 9558; E: acn@genmab.com
https://www.globenewswire.com/Tracker?data=B_q-WyawknivetHdeD6UHKw94g5WnXswmyL8itCtBCduIRjGYbuLLCIs-znzv0fomcftTUn2Zbi2Rv9QfMxd1A==
This Company Announcement contains forward looking statements.
The words "believe", "expect", "anticipate", "intend" and "plan"
and similar expressions identify forward looking statements. Actual
results or performance may differ materially from any future
results or performance expressed or implied by such statements. The
important factors that could cause our actual results or
performance to differ materially include, among others, risks
associated with pre-clinical and clinical development of products,
uncertainties related to the outcome and conduct of clinical trials
including unforeseen safety issues, uncertainties related to
product manufacturing, the lack of market acceptance of our
products, our inability to manage growth, the competitive
environment in relation to our business area and markets, our
inability to attract and retain suitably qualified personnel, the
unenforceability or lack of protection of our patents and
proprietary rights, our relationships with affiliated entities,
changes and developments in technology which may render our
products or technologies obsolete, and other factors. For a further
discussion of these risks, please refer to the risk management
sections in Genmab's most recent financial reports, which are
available on
https://www.globenewswire.com/Tracker?data=stxnem1C6w9skUw70yYHawIy_xT-AvWckGTgWzEAbnKdHCOfkBWlOER-9y2RMGfcU7eLmFPJZWxpRg6n70NJJg==
www.genmab.com and the risk factors included in Genmab's most
recent Annual Report on Form 20-F and other filings with the U.S.
Securities and Exchange Commission (SEC), which are available at
https://www.globenewswire.com/Tracker?data=stxnem1C6w9skUw70yYHa3tTlI1_o-chvF_eJyyWXVCGo5BRRkDGDUStjBHm-Y-4H6BL4iYr7CCqYpAD4YLazXvGvI-Y7UTQkB3tZXOOBxw=
www.sec.gov. Genmab does not undertake any obligation to update or
revise forward looking statements in this Company Announcement nor
to confirm such statements to reflect subsequent events or
circumstances after the date made or in relation to actual results,
unless required by law.
Genmab A/S and/or its subsidiaries own the following trademarks:
Genmab(R) ; the Y-shaped Genmab logo(R) ; Genmab in combination
with the Y-shaped Genmab logo(R) ; HuMax(R) ; DuoBody(R) ; DuoBody
in combination with the DuoBody logo(R) ; HexaBody(R) ; HexaBody in
combination with the HexaBody logo(R) ; DuoHexaBody(R) and
HexElect(R) .
Company Announcement no. 64
CVR no. 2102 3884
LEI Code 529900MTJPDPE4MHJ122
Genmab A/S
Kalvebod Brygge 43
1560 Copenhagen V
Denmark
Attachment
-- 071021_CA64_Warrant Grant
https://ml-eu.globenewswire.com/Resource/Download/4d110d0f-3576-4a60-8b77-7c94928c061c
(END) Dow Jones Newswires
October 07, 2021 14:55 ET (18:55 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Genuit (LSE:GEN)
Historical Stock Chart
From Apr 2024 to May 2024
Genuit (LSE:GEN)
Historical Stock Chart
From May 2023 to May 2024